December 16, 2025

Vertero Strengthens Board of Directors with Appointment of Independent Chair R. Scott Greer

December 10, 2025

Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases

December 4, 2025

Vertero Appoints Jeffrey Kasten as Chief Business Officer

November 24, 2025

Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease

October 21, 2025

Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases